Bicara Therapeutics Reports Q1 2026 Financial Results and Updates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 hours ago
0mins
Should l Buy BCAX?
Source: Newsfilter
- Clinical Trial Progress: Bicara Therapeutics continues to advance the FORTIFI-HN01 pivotal trial in Q1 2026, expecting substantial enrollment by year-end to enable an interim analysis in mid-2027, paving the way for potential accelerated approval.
- New Dosing Regimen Study: The company plans to initiate a randomized clinical study in Q3 2026 to evaluate a loading dose and every-three-week maintenance regimen of ficerafusp alfa in combination with pembrolizumab, aiming to further differentiate the therapy and expand options for patients and providers.
- Executive Changes: Bill Schelman has been appointed Chief Medical Officer, succeeding David Raben, who transitions to a Senior Executive Advisor role, while Chris Sarchi is appointed Chief Commercial Officer, indicating the company's commitment to evolving into a commercial-stage entity.
- Financial Performance: As of March 31, 2026, Bicara reported cash and cash equivalents of $539.8 million, a significant increase from $414.8 million at the end of 2025, while the net loss for Q1 2026 was $56.2 million, up from $36.8 million in the same period last year, reflecting ongoing investments in R&D.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCAX
Wall Street analysts forecast BCAX stock price to rise
11 Analyst Rating
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 22.580
Low
11.00
Averages
30.80
High
48.00
Current: 22.580
Low
11.00
Averages
30.80
High
48.00
About BCAX
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bicara Therapeutics Reports Q1 2026 Financial Results and Updates
- Clinical Trial Progress: Bicara Therapeutics continues to advance the FORTIFI-HN01 pivotal trial in Q1 2026, expecting substantial enrollment by year-end to enable an interim analysis in mid-2027, paving the way for potential accelerated approval.
- New Dosing Regimen Study: The company plans to initiate a randomized clinical study in Q3 2026 to evaluate a loading dose and every-three-week maintenance regimen of ficerafusp alfa in combination with pembrolizumab, aiming to further differentiate the therapy and expand options for patients and providers.
- Executive Changes: Bill Schelman has been appointed Chief Medical Officer, succeeding David Raben, who transitions to a Senior Executive Advisor role, while Chris Sarchi is appointed Chief Commercial Officer, indicating the company's commitment to evolving into a commercial-stage entity.
- Financial Performance: As of March 31, 2026, Bicara reported cash and cash equivalents of $539.8 million, a significant increase from $414.8 million at the end of 2025, while the net loss for Q1 2026 was $56.2 million, up from $36.8 million in the same period last year, reflecting ongoing investments in R&D.
See More
Bicara Therapeutics CMO Executes Stock Sale
- Insider Stock Sale: David Raben, CMO of Bicara Therapeutics, sold 5,500 shares on April 27, 2026, for approximately $126,000, indicating active insider participation in the market.
- Holding Change Analysis: The transaction reduced Raben's direct ownership by 9.05%, yet he retains 55,286 shares and 41,913 options, reflecting ongoing confidence in the company's future prospects.
- Market Performance: As of April 27, 2026, Bicara's stock closed at $22.48, with a market cap of $1.4 billion; despite a reported net loss of $137.95 million in 2025, the stock has risen nearly 30% year-to-date, showcasing investor optimism for future growth.
- Upcoming Earnings Report: Bicara is set to release its Q1 2026 financial results on May 11, with investors keenly awaiting insights into the company's ongoing development in the biopharmaceutical sector.
See More
Bicara Therapeutics to Report Q1 2026 Financial Results and Host Conference Call
- Earnings Release Schedule: Bicara Therapeutics is set to announce its Q1 2026 financial results and business updates before the market opens on May 11, 2026, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call at 8:30 AM ET on the same day to discuss the financial results and business updates, requiring participants to register in advance for dial-in information, reflecting the importance placed on investor relations.
- Therapeutic Platform Overview: Bicara focuses on developing bifunctional therapies aimed at improving treatment outcomes for patients with solid tumors by precisely targeting tumors and delivering modulating payloads, showcasing its innovative potential in the biopharmaceutical sector.
- Key Product Progress: The lead product, ficerafusp alfa, combines an EGFR monoclonal antibody with a TGF-β ligand trap, aiming to simultaneously block tumor cell survival and proliferation signals, which could significantly enhance patient survival rates.
See More
Bicara Therapeutics Grants Stock Options to New Employee
- Stock Option Grant: Bicara Therapeutics awarded a new employee 44,175 non-qualified stock options on April 1, 2026, with an exercise price of $20.50 per share, reflecting the company's commitment to attracting talent.
- Vesting Schedule: One-fourth of the options will vest on the first anniversary of the employee's start date, with the remaining shares vesting in 12 equal quarterly installments, ensuring ongoing contributions from the employee during their tenure.
- Inducement Plan Context: This grant was made under Bicara's 2026 Inducement Plan, approved by the board in January 2026, in compliance with Nasdaq Listing Rule 5635(c)(4), highlighting the company's focus on regulatory adherence.
- R&D Strategy: Bicara is dedicated to developing bifunctional therapies, particularly ficerafusp alfa for head and neck squamous cell carcinoma, aiming to enhance treatment efficacy by precisely targeting the tumor microenvironment and addressing significant unmet medical needs.
See More
Bicara Therapeutics CEO Sells Stock Options
- Stock Option Exercise: Bicara Therapeutics CEO Claire Mazumdar exercised 8,234 stock options and immediately sold them for approximately $154,000, indicating a focus on liquidity while maintaining direct holdings of 339,392 shares valued at about $6.36 million.
- Ownership Change: Mazumdar's direct ownership decreased by 2.37%, yet she retains an additional 227,873 exercisable options, suggesting optimism about the company's future potential despite the short-term reduction in her ownership percentage.
- Market Context: The transaction occurred between March 4 and 6, 2026, with stock prices fluctuating between $18.25 and $18.47, reflecting a 30.60% increase in share price over the past year, indicating market confidence in its treatment solutions.
- Investor Impact Assessment: This transaction is not significant for investors as it was part of a Rule 10b5-1 trading plan, and with clinical trials progressing well despite a net loss of $138 million, investors must weigh risks against potential returns.
See More
Bicara Therapeutics CEO Sells Shares Amid Strong Stock Performance
- Executive Share Sale: Bicara Therapeutics CEO Claire Mazumdar sold 8,234 common shares between March 4 and 6, 2026, for approximately $154,000 at an average price of $18.74 per share, representing a 2.37% reduction in her direct holdings to 339,392 shares, indicating executive selling at a market high.
- Transaction Context: This sale was part of Mazumdar's Rule 10b5-1 trading plan established in February 2025, designed to avoid insider trading accusations, with all shares held directly, suggesting her continued optimism about the company's future without an urgent need to liquidate.
- Financial Performance: Despite the stock reaching a 52-week high of $20.25, Bicara reported a net loss of $138 million in 2025, significantly up from a $68 million loss in 2024, highlighting soaring research costs and necessitating cautious investor assessment of risks.
- Market Outlook and Investment Advice: While clinical trials for its therapies are progressing well, Bicara has yet to generate sales, requiring investor belief in the potential for federal approval and revenue generation; the current stock price increase presents a good selling opportunity, but holding or buying shares involves weighing potential returns against risks.
See More
Bicara Therapeutics Reports Q1 2026 Financial Results and Updates
- Clinical Trial Progress: Bicara Therapeutics continues to advance the FORTIFI-HN01 pivotal trial in Q1 2026, expecting substantial enrollment by year-end to enable an interim analysis in mid-2027, paving the way for potential accelerated approval.
- New Dosing Regimen Study: The company plans to initiate a randomized clinical study in Q3 2026 to evaluate a loading dose and every-three-week maintenance regimen of ficerafusp alfa in combination with pembrolizumab, aiming to further differentiate the therapy and expand options for patients and providers.
- Executive Changes: Bill Schelman has been appointed Chief Medical Officer, succeeding David Raben, who transitions to a Senior Executive Advisor role, while Chris Sarchi is appointed Chief Commercial Officer, indicating the company's commitment to evolving into a commercial-stage entity.
- Financial Performance: As of March 31, 2026, Bicara reported cash and cash equivalents of $539.8 million, a significant increase from $414.8 million at the end of 2025, while the net loss for Q1 2026 was $56.2 million, up from $36.8 million in the same period last year, reflecting ongoing investments in R&D.
See More
Bicara Therapeutics CMO Executes Stock Sale
- Insider Stock Sale: David Raben, CMO of Bicara Therapeutics, sold 5,500 shares on April 27, 2026, for approximately $126,000, indicating active insider participation in the market.
- Holding Change Analysis: The transaction reduced Raben's direct ownership by 9.05%, yet he retains 55,286 shares and 41,913 options, reflecting ongoing confidence in the company's future prospects.
- Market Performance: As of April 27, 2026, Bicara's stock closed at $22.48, with a market cap of $1.4 billion; despite a reported net loss of $137.95 million in 2025, the stock has risen nearly 30% year-to-date, showcasing investor optimism for future growth.
- Upcoming Earnings Report: Bicara is set to release its Q1 2026 financial results on May 11, with investors keenly awaiting insights into the company's ongoing development in the biopharmaceutical sector.
See More
Bicara Therapeutics to Report Q1 2026 Financial Results and Host Conference Call
- Earnings Release Schedule: Bicara Therapeutics is set to announce its Q1 2026 financial results and business updates before the market opens on May 11, 2026, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call at 8:30 AM ET on the same day to discuss the financial results and business updates, requiring participants to register in advance for dial-in information, reflecting the importance placed on investor relations.
- Therapeutic Platform Overview: Bicara focuses on developing bifunctional therapies aimed at improving treatment outcomes for patients with solid tumors by precisely targeting tumors and delivering modulating payloads, showcasing its innovative potential in the biopharmaceutical sector.
- Key Product Progress: The lead product, ficerafusp alfa, combines an EGFR monoclonal antibody with a TGF-β ligand trap, aiming to simultaneously block tumor cell survival and proliferation signals, which could significantly enhance patient survival rates.
See More
Bicara Therapeutics Grants Stock Options to New Employee
- Stock Option Grant: Bicara Therapeutics awarded a new employee 44,175 non-qualified stock options on April 1, 2026, with an exercise price of $20.50 per share, reflecting the company's commitment to attracting talent.
- Vesting Schedule: One-fourth of the options will vest on the first anniversary of the employee's start date, with the remaining shares vesting in 12 equal quarterly installments, ensuring ongoing contributions from the employee during their tenure.
- Inducement Plan Context: This grant was made under Bicara's 2026 Inducement Plan, approved by the board in January 2026, in compliance with Nasdaq Listing Rule 5635(c)(4), highlighting the company's focus on regulatory adherence.
- R&D Strategy: Bicara is dedicated to developing bifunctional therapies, particularly ficerafusp alfa for head and neck squamous cell carcinoma, aiming to enhance treatment efficacy by precisely targeting the tumor microenvironment and addressing significant unmet medical needs.
See More
Bicara Therapeutics CEO Sells Stock Options
- Stock Option Exercise: Bicara Therapeutics CEO Claire Mazumdar exercised 8,234 stock options and immediately sold them for approximately $154,000, indicating a focus on liquidity while maintaining direct holdings of 339,392 shares valued at about $6.36 million.
- Ownership Change: Mazumdar's direct ownership decreased by 2.37%, yet she retains an additional 227,873 exercisable options, suggesting optimism about the company's future potential despite the short-term reduction in her ownership percentage.
- Market Context: The transaction occurred between March 4 and 6, 2026, with stock prices fluctuating between $18.25 and $18.47, reflecting a 30.60% increase in share price over the past year, indicating market confidence in its treatment solutions.
- Investor Impact Assessment: This transaction is not significant for investors as it was part of a Rule 10b5-1 trading plan, and with clinical trials progressing well despite a net loss of $138 million, investors must weigh risks against potential returns.
See More
Bicara Therapeutics CEO Sells Shares Amid Strong Stock Performance
- Executive Share Sale: Bicara Therapeutics CEO Claire Mazumdar sold 8,234 common shares between March 4 and 6, 2026, for approximately $154,000 at an average price of $18.74 per share, representing a 2.37% reduction in her direct holdings to 339,392 shares, indicating executive selling at a market high.
- Transaction Context: This sale was part of Mazumdar's Rule 10b5-1 trading plan established in February 2025, designed to avoid insider trading accusations, with all shares held directly, suggesting her continued optimism about the company's future without an urgent need to liquidate.
- Financial Performance: Despite the stock reaching a 52-week high of $20.25, Bicara reported a net loss of $138 million in 2025, significantly up from a $68 million loss in 2024, highlighting soaring research costs and necessitating cautious investor assessment of risks.
- Market Outlook and Investment Advice: While clinical trials for its therapies are progressing well, Bicara has yet to generate sales, requiring investor belief in the potential for federal approval and revenue generation; the current stock price increase presents a good selling opportunity, but holding or buying shares involves weighing potential returns against risks.
See More
